by Chemiluminescence imaging has emerged as a widely used technique for biological assays and diagnostic applications. Chemiluminescence imaging uses a chemical reaction where two substances interact to produce light in the visible region of the electromagnetic spectrum. It is commonly employed in immunoassays using antibodies tagged with an enzyme like horseradish peroxidase or alkaline phosphatase. These enzymes catalyze the oxidation of luminol or other luminogenic substrates to produce light. Several diagnostic kits rely on chemiluminescence imaging to detect the presence of antigens or antibodies related to various diseases and conditions. It is a highly sensitive technique and provides quantitative results without requiring radioactive tracers. The equipment used is relatively inexpensive compared to other molecular imaging modalities. With the rising prevalence of chronic and infectious diseases worldwide, the diagnostic demand has surged significantly. Moreover, continuous technological advancements are helping improve the efficiency and throughput of chemiluminescence imaging systems.
The global Chemiluminescence Imaging Market is estimated to be valued at US$ 13.2 Bn in 2023 and is expected to exhibit a CAGR of 7.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the Global chemiluminescence imaging market Size is the development of high-throughput systems. Companies are focusing on designing systems that can process large numbers of samples and provide quicker results. For instance, microplate luminometers can analyze 96-well or 384-well plates simultaneously. This significantly improves the productivity for applications like drug screening and industrial testing. Another trend is the miniaturization of chemiluminescence assays. Technologies like microfluidics are enabling the development of portable and point-of-care chemiluminescence devices with minimal sample requirements. This decentralized testing approach brings diagnostics closer to patients. Lastly, the integration of chemiluminescence with other modalities like fluorescence is expanding its applications. Dual-mode systems offer enhanced multiplexing capabilities and imaging options for advanced research techniques. The combination of chemiluminescence imaging with microscopes, DNA arrays, and flow cytometry devices holds promise.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate to high due to high capital required for R&D and manufacturing of chemiluminescence imaging equipment. However, strategic partnerships with existing players can lower the entry barriers.
Bargaining power of buyers: The bargaining power of buyers is moderate as the buyers have many established global players to choose from offering prices and quality variations.
Bargaining power of suppliers: The bargaining power of suppliers is low as raw materials used in manufacturing chemiluminescence imaging equipment are commonly available.
Threat of new substitutes: The threat of substitutes is low as fluorescence, radioisotope imaging methods cannot substitute all applications of chemiluminescence imaging.
Competitive rivalry: The industry faces high competitive rivalry owing to presence of large established as well as emerging global players continuously investing in R&D and new product launches.
Key Takeaways
The global chemiluminescence imaging market is expected to witness high growth over the forecast period of 2023 to 2030. The global chemiluminescence imaging market is estimated to be valued at US$ 13.2 billion in 2023 and is expected to exhibit a CAGR of 7.5% over the forecast period 2023 to 2030.
Regional analysis shows that North America dominated the market in 2023 with a share of around 35% due to presence of major players and high adoption of advanced imaging techniques in research and diagnostics in the region. Europe and Asia Pacific are expected to be the fastest growing markets during the forecast period with CAGRs of around 8% owing to growing life sciences research, expanding biopharma industry and increasing healthcare expenditure in countries like China and India.
Key players operating in the chemiluminescence imaging market are Azure Biosystems, Inc.,Berthold Technologies GmbH & Co. KG,Carestream Health, Inc.,GE Healthcare,LI-COR Biosciences,PerkinElmer, Inc.,Syngene International Limited,Tecan Trading AG,Thermo Fisher Scientific Inc.,UVItec Limited. Players are focused on new product launches, geographic expansions and partnerships with research institutes to strengthen their market presence. For instance, in 2023, Azure Biosystems launched Nanoimager CHL for chemiluminescence detection in DNA/RNA and protein gels & blots, expanding its life science tools portfolio.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
